Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pregnancy DNA test may spot cancer in Moms-to-Be

NCT ID NCT07448025

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal patterns linked to malignant disease. The goal is to improve how such unexpected findings are handled and potentially create guidelines for early cancer detection during pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a way to spot maternal cancers early using standard pregnancy blood tests, potentially saving lives.
What could go wrong
This is an observational study, not a treatment trial. It may not prove the test reliably detects cancer, and false alarms could cause anxiety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cases: Pregnant patients with a cancer diagnosis known before pregnancy or discovered during pregnancy. The comparison data (controls) will be provided in a database that will be compiled progressively by the Cerba laboratory throughout the inclusion period of the case patients. In this database, data from pregnant patients who underwent a circulating cell-free DNA (cfDNA) test as part of routine care and who were free of any known cancer at the time of sampling for the cfDNA test will be identified.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria (Cases): * Adult patient (≥18 years old); * Pregnant patient with a cancer known prior to pregnancy or diagnosed during pregnancy; * Pregnancy at a gestational age \> 10 weeks of amenorrhea at the time of inclusion; * Patient informed and having signed the informed consent form to participate in the study. Exclusion Criteria: * Multiple pregnancy; * Patient with a history of organ transplantation; Patient having received an allogeneic stem cell transplant; * Known maternal mosaic chromosomal abnormality and copy number variation (CNV); * Patient presenting with one or more known uterine fibroids at the time of inclusion; * Technical inability to conduct a teleconsultation via a secure video connection and to complete an electronic signature.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer malignancy diagnosed during pregnancy neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Femmes enceintes Pregnant women with cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP - Antoine Béclère hospital

    Clamart, 94141, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.